Liberty Journal

The indefensible approval of Pfizer and Merck drugs compared to the snubbing of ivermectin

I sometimes wonder how long it will be until the horror of what we’ve done during Covid will be realized and accepted. When we see that money and power were deemed more important than people what will we do?

Later this week, the FDA plans to approve, as the first outpatient COVID drugs, therapeutics that are extremely dangerous and unproven, even as the agency goes to war against cheap, safe, and proven drugs with a track record of no serious adverse events. The approval is as shocking as it is revealing and should serve as a warning to those who don’t believe the FDA would approve vaccines that aren’t safe and effective.

We already know that every drug the FDA has approved so far for inpatient treatment has an FDA “black box warning” for serious adverse events. At present, the only approved drugs in-patient are remdesivir, baricitinib, and tofacitinib. None of them have demonstrated any efficacy over a year of their use, and remdesivir is known to cause liver toxicity and renal failure. Baricitinib (brand name Olumiant) has an FDA black box warning for blood clots, of all things! Tofacitinib (brand name Xeljanz) has a black box warning for “serious infections and malignancy.” Now, let me introduce you to the first candidates for outpatient treatment: Merck’s molnupiravir (brand name Lagevrio) and Pfizer’s Paxlovid.

I’ve already written extensively on molnupiravir. Even the FDA advisory committee admitted that the drug poses a risk of birth defects, is mutagenic, has a dangerous mechanism of action, and was never studied for carcinogenicity, and its second-phase trial showed greater “efficacy” in the placebo group than the trial group. Even the mainstream media has warned that the drug really is not up to snuff, yet shockingly, the FDA is set to give it approval, as if basic safety and efficacy facts no longer matter. This move in itself, in conjunction with what we know about the approved inpatient drugs, should tell you everything you need to know about the juxtaposition of the vaccine approval to the war on ivermectin and hydroxychloroquine and the refusal to approve or encourage the use of numerous other safe and effective drugs.

But what about Pfizer’s Paxlovid? Doesn’t that have a safer mechanism of action, similar to that of ivermectin? And wasn’t it proven 89% effective in reducing mortality and hospitalization?

Efficacy of Pfizer’s Paxlovid

Unlike Merck’s drug, which has a known dangerous mechanism of action as a nucleotide analogue, Paxlovid is more of a defensive drug as a 3CL protease inhibitor. Dr. Ryan Cole, a clinical and anatomic pathologist who has studied the replication process of SARS-CoV-2 and its treatments in more depth than almost anyone on the planet, explains the mechanism as follows:

When COVID replicates inside our cells, part of the process is formation of a long string of amino acids within our cell’s ribosome (hijacked by the virus to use as a protein manufacturing site), forming a chain of proteins called a polyprotein. In order for the proteins to form the parts of the virus, this chain must be clipped and broken down into the viral protein parts. An enzyme called a protease does this cutting and clipping. Paxlovid is a protease inhibitor, meaning it binds to this enzyme “scissors” and keeps the cutting from happening, so the virus cannot reassemble.
Sounds terrific, right?

Here’s the problem. Do you know what else is also the most effective protease inhibitor on the market? Ivermectin. And it also has at least 19 other mechanisms of action, which include anti-coagulant (inhibits CD147 receptor binding) and anti-inflammatory (decreases IL-6 and other inflammatory cytokines) modes of action. Paxlovid has none of these mechanisms. So why would we rely on an expensive drug with one of ivermectin’s 20 mechanisms of action – yes, 20 – that does not have an established safety profile when we can use an off-patent drug with the safest profile imaginable and mechanisms that work even in advanced stages? Also, Cole explains that because Paxlovid only has one…

Continue reading>>>